Gastroenterology Research and Practice / 2017 / Article / Tab 3

Research Article

Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors

Table 3

Association with metastatic disease at diagnosis (stage IIIB-IV) according to log-rank regression test.

VariableUnivariateMultivariate
ORCI 95%ORCI 95%

Male gender1.2960.5–3.50.611
No syndrome1.4440.4–4.80.546
GI-NET2.4930.9–6.90.079ns
Grading G213.3643.7–47.9<0.00177.0255.6–1064.20.001
Low SSTR2A QS15.4004.3–55.8<0.001121.3426.8–2174.90.001
Low IGF-1R QS5.7271.9–16.90.002ns
High p-mTOR QS12.4293.1–49.3<0.00180.9864.9–1353.70.002

OR: odds ratio; CI: confidence interval; ns: not statistically significant; GI-NET: gastrointestinal primary NET (versus pancreatic NET); SSTR2A: somatostatin receptor 2A; IGF-1R: insulin-like growth factor-1 receptor; p-mTOR: phosphorylated mammalian target of rapamycin; QS: quantitative score.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.